Georgiou, Polymnia

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 1,609

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms

Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 1,260

( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions

Zanos, P., Highland, J. N., Stewart, B. W., Georgiou, P., Jenne, C. E., Lovett, J., Morris, P. J., Thomas, C. J., Moaddel, R., Zarate, C. A., et al. (2019) · Proceedings of the National Academy of Sciences

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 152

The oxytocin analogue carbetocin prevents emotional impairment and stress-induced reinstatement of opioid-seeking in morphine-abstinent mice

Zanos, P., Georgiou, P., Wright, S. R., Hourani, S. M., Kitchen, I., Winsky-Sommerer, R., & Bailey, A. (2014) · Neuropsychopharmacology

Neuroendocrine regulation and behaviorNeuropeptides and Animal Physiology

Cited by 133

NMDA Receptor Activation-Dependent Antidepressant-Relevant Behavioral and Synaptic Actions of Ketamine

Zanos, P., Brown, K. A., Georgiou, P., Yuan, P., Zarate, C. A., Thompson, S. M., & Gould, T. D. (2023) · The Journal of Neuroscience

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 115

A negative allosteric modulator for α5 subunit-containing GABA receptors exerts a rapid and persistent antidepressant-like action without the side effects of the NMDA receptor antagonist ketamine in mice

Zanos, P., Nelson, M. E., Highland, J. N., Krimmel, S. R., Georgiou, P., Gould, T. D., & Thompson, S. M. (2017) · eNeuro

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 106

Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications

Highland, J. N., Zanos, P., Riggs, L. M., Georgiou, P., Clark, S. M., Morris, P. J., Moaddel, R., Thomas, C. J., Zarate, C. A., Pereira, E. F. R., et al. (2021) · Pharmacological Reviews

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 92

(R)‐Ketamine exerts antidepressant actions partly via conversion to (2R,6R)‐hydroxynorketamine, while causing adverse effects at sub‐anaesthetic doses

Zanos, P., Highland, J. N., Liu, X., Troppoli, T. A., Georgiou, P., Lovett, J., Morris, P. J., Stewart, B. W., Thomas, C. J., Thompson, S. M., et al. (2019) · British Journal of Pharmacology

Treatment of Major DepressionTryptophan and brain disorders

Cited by 82

Negative Allosteric Modulation of Gamma-Aminobutyric Acid A Receptors at α5 Subunit–Containing Benzodiazepine Sites Reverses Stress-Induced Anhedonia and Weakened Synaptic Function in Mice

Troppoli, T. A., Zanos, P., Georgiou, P., Gould, T. D., Rudolph, U., & Thompson, S. M. (2022) · Biological Psychiatry

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 29

Transient anhedonia phenotype and altered circadian timing of behaviour during night-time dim light exposure in Per3−/− mice, but not wildtype mice

Martynhak, B. J., Hogben, A. L., Zanos, P., Georgiou, P., Andreatini, R., Kitchen, I., Archer, S. N., von Schantz, M., Bailey, A., & van der Veen, D. R. (2017) · Scientific Reports

Circadian rhythm and melatoninSleep and Wakefulness Research

Cited by 23

Classical conditioning of antidepressant placebo effects in mice

Krimmel, S. R., Zanos, P., Georgiou, P., Colloca, L., & Gould, T. D. (2020) · Psychopharmacology

Pain Management and Placebo EffectTreatment of Major Depression

Cited by 12